Cancer Genetics to Buy PGx Firm Gentris for up to $6.25M | GenomeWeb

NEW YORK (GenomeWeb) – Cancer Genetics today announced it has signed a non-binding letter of intent to buy Gentris for up to $6.25 million.

The deal, which will be treated as an asset purchase, is made up of $3.25 million in cash and $1.5 million in Cancer Genetics stock. It also includes up to $1.5 million from Cancer Genetics in performance-based earn-outs. The acquisition is expected to close in the third quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.